Diagonal Bio AB Statistics
Total Valuation
Diagonal Bio AB has a market cap or net worth of SEK 10.93 million. The enterprise value is 6.43 million.
Market Cap | 10.93M |
Enterprise Value | 6.43M |
Important Dates
The next estimated earnings date is Friday, August 22, 2025.
Earnings Date | Aug 22, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Diagonal Bio AB has 1.21 billion shares outstanding. The number of shares has increased by 1,106.71% in one year.
Current Share Class | 1.21B |
Shares Outstanding | 1.21B |
Shares Change (YoY) | +1,106.71% |
Shares Change (QoQ) | +90.05% |
Owned by Insiders (%) | 13.09% |
Owned by Institutions (%) | 3.57% |
Float | 1.01B |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 8.05 |
PB Ratio | 0.39 |
P/TBV Ratio | 0.44 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -0.68 |
EV / Sales | 4.74 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45
Current Ratio | 2.45 |
Quick Ratio | 1.83 |
Debt / Equity | n/a |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -28.64 |
Financial Efficiency
Return on equity (ROE) is -40.60% and return on invested capital (ROIC) is -24.71%.
Return on Equity (ROE) | -40.60% |
Return on Assets (ROA) | -19.37% |
Return on Invested Capital (ROIC) | -24.71% |
Return on Capital Employed (ROCE) | -32.49% |
Revenue Per Employee | 339,500 |
Profits Per Employee | -2.37M |
Employee Count | 5 |
Asset Turnover | 0.05 |
Inventory Turnover | 0.28 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.94% in the last 52 weeks. The beta is -1.88, so Diagonal Bio AB's price volatility has been lower than the market average.
Beta (5Y) | -1.88 |
52-Week Price Change | -60.94% |
50-Day Moving Average | 0.01 |
200-Day Moving Average | 0.02 |
Relative Strength Index (RSI) | 37.83 |
Average Volume (20 Days) | 11,256,883 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Diagonal Bio AB had revenue of SEK 1.36 million and -9.47 million in losses. Loss per share was -0.02.
Revenue | 1.36M |
Gross Profit | 1.03M |
Operating Income | -9.22M |
Pretax Income | -9.47M |
Net Income | -9.47M |
EBITDA | -8.74M |
EBIT | -9.22M |
Loss Per Share | -0.02 |
Balance Sheet
The company has 4.50 million in cash and n/a in debt, giving a net cash position of 4.50 million or 0.00 per share.
Cash & Cash Equivalents | 4.50M |
Total Debt | n/a |
Net Cash | 4.50M |
Net Cash Per Share | 0.00 |
Equity (Book Value) | 28.39M |
Book Value Per Share | 0.02 |
Working Capital | 3.79M |
Cash Flow
Operating Cash Flow | -22.61M |
Capital Expenditures | n/a |
Free Cash Flow | n/a |
FCF Per Share | n/a |
Margins
Gross Margin | 75.77% |
Operating Margin | -679.16% |
Pretax Margin | -697.35% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
Diagonal Bio AB does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -1,106.71% |
Shareholder Yield | n/a |
Earnings Yield | -86.61% |
FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Diagonal Bio AB has an Altman Z-Score of 0.57 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 0.57 |
Piotroski F-Score | 1 |